IP Library › Granted Patent US 12,201,594
Granted Patent B2
US 12,201,594 · App. 17/339,414 · Granted Jan 21, 2025

Methods and compositions for treatment of pain using capsaicin

Inventors: James N. Campbell (Baltimore, MD); Peter D. Hanson (Prides Crossing, MA); Randall Stevens (Rockport, MA)
Assignee: Centrexion Therapeutics Corporation
A61K31/167A61F7/10A61K9/0014A61K9/0019A61P19/02A61F2007/0042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,594
App. No.
17/339,414
Granted
Jan 21, 2025
Kind
B2
Abstract

The invention provides methods and compositions for treatment of pain, such as joint pain, using capsaicin in a procedure that attenuates transient burning sensation experienced by patients due to capsaicin administration. The methods desirably provide relief from joint pain, such as osteoarthritic knee joint pain, for an extended duration, such as at least about 3 months, 6 months, 9 months, or 1 year. To attenuate the adverse side effect of a transient burning sensation caused by capsaicin-induced neuronal excitation, the methods utilize a cooling article, such as a material wrap cooled via a circulating fluid, to reduce the temperature of tissue to be exposed to capsaicin to within a certain range for certain durations of time, optionally in combination with administering a local anesthetic agent, resulting in the substantial reduction or even elimination of transient burning sensation caused by capsaicin.

Claims (45)

1. A method of ameliorating joint pain in a human patient, comprising:

a. optionally applying a cooling article to a human patient's skin in proximity to a joint in need of pain relief therapy; then

b. optionally administering a local anesthetic agent into said joint; then

c. applying a cooling article to the patient's skin in proximity to said joint to achieve a temperature in the range of from 28° C. to 30° C. for tissue or fluid in the interior of the joint; then

d. administering by injection into said joint a pharmaceutical composition comprising capsaicin in order to deliver a dose of capsaicin in an amount of 1 mg; and then the joint is flexed 5 times; and then

e. optionally applying a cooling article to the patient's skin in proximity to said joint; to thereby ameliorate joint pain in the human patient,

wherein the joint pain is osteoarthritic joint pain, the joint is a knee joint, and

the following additional step is performed between steps (c) and (d): administering into said joint a pharmaceutical composition comprising a single pain-relief local anesthetic agent selected from the group consisting of lidocaine and a pharmaceutically acceptable salt thereof, in order to deliver a dose of lidocaine in an amount ranging from about 0.1 g to about 0.5 g;

wherein the patient does not receive any pain-relief medicine other than (i) the local anesthetic agent recited in step (b) and in said additional step between steps (c) and (d) and (ii) capsaicin.

2. The method of claim 1 , wherein the method does not contain step (a).

3. The method of claim 2 , wherein the method does not contain step (b).

4. The method of claim 3 , wherein step (c) comprises applying a cooling article to the patient's skin in proximity to the joint to achieve a temperature of 28° C. for tissue or fluid in the interior of the joint.

5. The method of claim 3 , wherein step (c) comprises applying a cooling article to the patient's skin in proximity to the joint to achieve a temperature of 29° C. for tissue or fluid in the interior of the joint.

6. The method of claim 3 , wherein step (c) comprises applying a cooling article to the patient's skin in proximity to the joint to achieve a temperature of 30° C. for tissue or fluid in the interior of the joint.

7. The method of claim 3 , wherein the cooling article has an exterior surface temperature in the range of from about 5° C. to about 15° C. for application to the human patient's skin in proximity to said joint.

8. The method of claim 3 , wherein the cooling article has an exterior surface temperature in the range of from about 8° C. to about 10° C. for application to the human patient's skin in proximity to said joint.

9. The method of claim 3 , wherein the cooling article has an exterior surface temperature of about 9° C. for application to the human patient's skin in proximity to said joint.

10. The method of claim 7 , wherein step (c) comprises applying for a duration of about 30 minutes the cooling article to an exterior surface of said joint.

11. The method of claim 7 , wherein the dose of lidocaine is about 0.3 g.

12. The method of claim 7 , wherein the dose of lidocaine is about 0.15 g.

13. The method of claim 7 , wherein the patient experiences transient burning sensation no greater than level two on a visual analog scale ranging from zero to four, due to administering the pharmaceutical composition comprising capsaicin.

14. The method of claim 7 , wherein transient burning sensation is evaluated at about 30 minutes after administration of the pharmaceutical composition comprising capsaicin, and said transient burning sensation is no greater than level one on a visual analog scale ranging from zero to four, due to administering the pharmaceutical composition comprising capsaicin.

15. A method of ameliorating joint pain in a human patient, comprising:

a. optionally applying a cooling article to a human patient's skin in proximity to a joint in need of pain relief therapy; then

b. optionally administering a local anesthetic agent into said joint; then

c. applying a cooling article to the patient's skin in proximity to said joint to achieve a temperature in the range of from 28° C. to 30° C. for tissue or fluid in the interior of the joint; then

d. administering by injection into said joint a pharmaceutical composition comprising capsaicin in order to deliver a dose of capsaicin in an amount of 1 mg; and then the joint is flexed 5 times; and then

e. optionally applying a cooling article to the patient's skin in proximity to said joint; to thereby ameliorate joint pain in the human patient,

wherein the joint pain is osteoarthritic joint pain, the joint is a knee joint, and

the following additional step is performed between steps (c) and (d): administering into said joint a pharmaceutical composition comprising a single pain-relief local anesthetic agent selected from the group consisting of lidocaine and a pharmaceutically acceptable salt thereof, in order to deliver a dose of lidocaine in an amount ranging from about 0.1 g to about 0.5 g;

wherein the pharmaceutical composition comprising capsaicin does not contain hyaluronic acid.

16. The method of claim 15 , wherein the method does not contain step (a).

17. The method of claim 16 , wherein the method does not contain step (b).

18. The method of claim 17 , wherein step (c) comprises applying a cooling article to the patient's skin in proximity to the joint to achieve a temperature of 28° C. for tissue or fluid in the interior of the joint.

19. The method of claim 17 , wherein step (c) comprises applying a cooling article to the patient's skin in proximity to the joint to achieve a temperature of 29° C. for tissue or fluid in the interior of the joint.

20. The method of claim 17 , wherein step (c) comprises applying a cooling article to the patient's skin in proximity to the joint to achieve a temperature of 30° C. for tissue or fluid in the interior of the joint.

21. The method of claim 17 , wherein the cooling article has an exterior surface temperature in the range of from about 5° C. to about 15° C. for application to the human patient's skin in proximity to said joint.

22. The method of claim 17 , wherein the cooling article has an exterior surface temperature in the range of from about 8° C. to about 10° C. for application to the human patient's skin in proximity to said joint.

23. The method of claim 17 , wherein the cooling article has an exterior surface temperature of about 9° C. for application to the human patient's skin in proximity to said joint.

24. The method of claim 21 , wherein step (c) comprises applying for a duration of about 30 minutes the cooling article to an exterior surface of said joint.

25. The method of claim 21 , wherein the dose of lidocaine is about 0.3 g.

26. The method of claim 21 , wherein the dose of lidocaine is about 0.15 g.

27. The method of claim 21 , wherein the patient experiences transient burning sensation no greater than level two on a visual analog scale ranging from zero to four, due to administering the pharmaceutical composition comprising capsaicin.

28. The method of claim 21 , wherein transient burning sensation is evaluated at about 30 minutes after administration of the pharmaceutical composition comprising capsaicin, and said transient burning sensation is no greater than level one on a visual analog scale ranging from zero to four, due to administering the pharmaceutical composition comprising capsaicin.

29. The method of claim 15 , wherein the pharmaceutical composition comprising capsaicin has a volume of about 2 mL.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 073683/0099 →
SECURITY INTEREST Recorded Nov 21, 2025
From: CENTREXION THERAPEUTICS CORPORATION
To: ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 073683/0108 →
SECURITY INTEREST Recorded Jul 12, 2023
From: CENTREXION THERAPEUTICS CORPORATION
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 064256/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2022
From: CAMPBELL, JAMES N.; HANSON, PETER D.; STEVENS, RANDALL
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 060150/0192 →
Continuity (4)
Continuation 16984384 · Aug 4, 2020
Continuation 16631277
Provisional Application 62535003 · Jul 20, 2017
Related Publication 20210299072A1 · Sep 30, 2021
References Cited (138)
US 4599342A · LaHann · 1986 [cited by applicant]
US 5021450A · Blumberg · 1991 [cited by applicant]
US 5099030A · Gardner et al. · 1992 [cited by applicant]
US 5318960A · Toppo · 1994 [cited by applicant]
US 5431914A · Adekunle et al. · 1995 [cited by applicant]
US 5962532A · Campbell et al. · 1999 [cited by applicant]
US 5985860A · Toppo · 1999 [cited by applicant]
US 6060060A · Belgorod · 2000 [cited by applicant]
US 6248788B1 · Robbins et al. · 2001 [cited by applicant]
US 6277398B1 · Caruso · 2001 [cited by applicant]
US 7943166B2 · Muhammad et al. · 2011 [cited by applicant]
US 7964644B2 · Meyer · 2011 [cited by applicant]
US 8158682B2 · Sangameswaran et al. · 2012 [cited by applicant]
US 8263093B2 · Muhammad et al. · 2012 [cited by applicant]
US 8273390B2 · Muhammad et al. · 2012 [cited by applicant]
US 8338457B2 · Iadarola et al. · 2012 [cited by applicant]
US 8367733B2 · Burch et al. · 2013 [cited by applicant]
US 8420600B2 · Burch et al. · 2013 [cited by applicant]
US 8637569B2 · Birbara · 2014 [cited by applicant]
US 8703741B2 · Meyer · 2014 [cited by applicant]
US 8734770B2 · Muhammad et al. · 2014 [cited by applicant]
US 9044452B2 · Meyer · 2015 [cited by applicant]
US 9359316B1 · Husfeld et al. · 2016 [cited by applicant]
US 9956166B2 · Zucker et al. · 2018 [cited by applicant]
US 9956190B2 · Birbara et al. · 2018 [cited by applicant]
US 10493047B2 · Ostovic et al. · 2019 [cited by applicant]
US 10765649B2 · Ostovic et al. · 2020 [cited by applicant]
US 10772853B2 · Ostovic et al. · 2020 [cited by applicant]
US 11000490B2 · Ostovic et al. · 2021 [cited by applicant]
US 11026903B2 · Campbell · 2021 [cited by examiner]
US 11344516B2 · Ostovic et al. · 2022 [cited by applicant]
US 20030104085A1 · Yeomans · 2003 [cited by applicant]
US 20050020690A1 · Burch et al. · 2005 [cited by applicant]
US 20060148903A1 · Burch et al. · 2006 [cited by applicant]
US 20060222690A1 · Bley · 2006 [cited by applicant]
US 20070021338A1 · Hansen et al. · 2007 [cited by applicant]
US 20100047181A1 · Meyer · 2010 [cited by applicant]
US 20100196281A1 · Meyer · 2010 [cited by applicant]
US 20100234470A1 · Sangameswaran et al. · 2010 [cited by applicant]
US 20110245708A1 · Finkel et al. · 2011 [cited by applicant]
US 20110311952A1 · Fairfield et al. · 2011 [cited by applicant]
US 20130157985A1 · Bucks et al. · 2013 [cited by applicant]
US 20130245729A1 · Edelman et al. · 2013 [cited by applicant]
US 20130252925A1 · Bucks et al. · 2013 [cited by applicant]
US 20130280176A1 · Diezi et al. · 2013 [cited by applicant]
US 20130280177A1 · Raman et al. · 2013 [cited by applicant]
US 20130303495A1 · Dhingra et al. · 2013 [cited by applicant]
US 20140017313A1 · Coulter et al. · 2014 [cited by applicant]
US 20140142073A1 · Birbara et al. · 2014 [cited by applicant]
US 20140161889A1 · Mikulasik et al. · 2014 [cited by applicant]
US 20150132374A1 · Coulter et al. · 2015 [cited by applicant]
US 20150132396A1 · Coulter et al. · 2015 [cited by applicant]
US 20150133561A1 · Birbara et al. · 2015 [cited by applicant]
US 20150306233A1 · Chiou et al. · 2015 [cited by applicant]
US 20160339105A1 · Shah et al. · 2016 [cited by applicant]
US 20160346241A1 · Amrutkar et al. · 2016 [cited by applicant]
US 20160354315A1 · Li · 2016 [cited by applicant]
US 20170239198A1 · Muzari · 2017 [cited by applicant]
US 20170266139A1 · Burch et al. · 2017 [cited by applicant]
US 20180169039A1 · Muhammad et al. · 2018 [cited by applicant]
US 20180311189A1 · Campbell et al. · 2018 [cited by applicant]
US 20190022036A1 · Campbell et al. · 2019 [cited by applicant]
US 20190038573A1 · Westphal et al. · 2019 [cited by applicant]
US 20200046656A1 · Ostovic et al. · 2020 [cited by applicant]
US 20200093765A1 · Ostovic et al. · 2020 [cited by applicant]
US 20200093766A1 · Ostovic et al. · 2020 [cited by applicant]
US 20200206166A1 · Campbell et al. · 2020 [cited by applicant]
CN 101119713A · 2008 [cited by applicant]
CN 101507818A · 2009 [cited by applicant]
CN 102205127A · 2011 [cited by applicant]
CN 105960230A · 2016 [cited by applicant]
EP 0646372A1 · 1995 [cited by applicant]
EP 3119794B1 · 2017 [cited by applicant]
WO WO1996040079A1 · 1996 [cited by applicant]
WO WO1998020867A1 · 1998 [cited by applicant]
WO WO1998040070A1 · 1998 [cited by applicant]
WO WO2002076444A1 · 2002 [cited by applicant]
WO WO2004056305A2 · 2004 [cited by applicant]
WO WO2004058286A1 · 2004 [cited by applicant]
WO WO2006058140A2 · 2006 [cited by applicant]
WO WO2008005802A2 · 2008 [cited by applicant]
WO WO2014019095A1 · 2014 [cited by applicant]
WO WO2014075084A2 · 2014 [cited by applicant]
WO WO2014128233A1 · 2014 [cited by applicant]
WO WO2015052510A1 · 2015 [cited by applicant]
WO WO2015073577A1 · 2015 [cited by applicant]
WO WO2015198059A1 · 2015 [cited by applicant]
WO WO2015198350A1 · 2015 [cited by applicant]
WO WO2016077749A1 · 2016 [cited by applicant]
WO WO2016086063A1 · 2016 [cited by applicant]
WO WO2016126540A1 · 2016 [cited by applicant]
WO WO2017087803A1 · 2017 [cited by applicant]
WO WO2017127628A1 · 2017 [cited by applicant]
WO WO2017147146A1 · 2017 [cited by applicant]
WO WO2017205534A1 · 2017 [cited by applicant]
WO WO2018085476A1 · 2018 [cited by applicant]
WO WO2018217937A1 · 2018 [cited by applicant]
Burch Ronald, Carter Richard B, Lazar Jeff. Clarivate English Machine Translation of ES 2562025 T3. Mar. 2, 2016. p. 1-39 (Year: 2016). [cited by examiner]
Hu (International Journal of Pharmaceutics 618 (2022) 121696 p. 1-13) (Year: 2022). [cited by examiner]
U.S. Appl. No. 16/631,277, Methods and Compositions for Treatment of Pain Using Capsaicin, filed Jan. 15, 2020. [cited by applicant]
Akesson in “A comparison of two formulations of intradermal capsaicin as models of neuropathic pain in healthy volunteers” (2007) Master Thesis in Pharmacy; The University of Adelaide Australia. [cited by applicant]
Basith et al., “Harnessing the Therapeutic Potential of Capsaicin and its Analogues in Pain and Other Diseases,” Molecules, pp. 1-28, (2016). [cited by applicant]
Botz in “The role of sensory neuropeptides in mouse models of neuropathy and immune arthritis” (year 2015) University PECS, Medical School. [cited by applicant]
Cantillon et al. in “Preliminary safety, tolerability and efficacy of ALGRX 4975 in Osteoarthritis (OA) of the knee” in [cited by applicant]
Chen et al. in Arzneimittelforschung (2010) vol. 60(9), pp. 571-574 (Abstract only). [cited by applicant]
Clinicaltrials Publication: “Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain,” a clinical study description, available from clinicaltrials.gov… [cited by applicant]
Clinicaltrials Publication: “Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain,” a clinical study description, available from clinicaltrials.gov… [cited by applicant]
Clinicaltrials Publication: “The Effect of Injection Site Cooling on Pain Experienced After the Administration of CNTX-4975-05 Into the Knee,” a clinical study description, available from clinicaltrials.gov online on Ma… [cited by applicant]
Clinicaltrials Publication: “A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis,” a clinical study description, available from cli… [cited by applicant]
Clinicaltrials Publication for Study NCT02869867, available from clinicaltrials.gov online on Mar. 27, 2017. [cited by applicant]
Costanzo et al. in Cough (2014) 10:6; doi: 10.1186/1745-9974-10-6 (published Sep. 25, 2014). [cited by applicant]
Ezawa et al. in International Journal of Medicinal Chemistry (2016) Article ID 8723139, 9 pages. [cited by applicant]
Galano et al. in J. Phys. Chem. B (2012) vol. 116, pp. 1200-1208. [cited by applicant]
Gustafsson et al. in Br. J. Clin. Pharmacol. (2009) vol. 68(4), pp. 511-517. [cited by applicant]
Ha et al. in J. Pharm. Sci. (2002) vol. 91(10), pp. 2252-2264 (Abstract only). [cited by applicant]
Hanson et al. in “Safety and Tolerability of CNTX-4975 in Subjects with Chronic, Moderate to Severe Knee Pain Associated with Osteoarthritis (Oa): A Pilot Study,” presented as a poster at the American Pain Society Annua… [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for PCT/US2018/043094 mailed Oct. 12, 2018 (12 pages). [cited by applicant]
Kadekawa et al. in Am. J. Physiol. Renal Physiol. (2017) vol. 313, F796-F804. [cited by applicant]
Kistner et al. in Sci. Rep. (2016) vol. 6, p. 28621. [cited by applicant]
Knolle et al., “Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: A randomized, double-blind, placebo-controlled study,” Pain, vol. 154, pp. 2729-2736, (2013). [cited by applicant]
Kopec et al. in Cough (2008) 4:3 doi 10.1186/1745-9974-4-3 (published May 27, 2008). [cited by applicant]
Leffler et al., “The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons,” The Journal of Clinical Investigation, vol. 118, No. 2, pp. 763-776, (2008). [cited by applicant]
Med Device Online publication entitled “New Motorized Cold Therapy System Introduced” (published Jun. 14, 2005). [cited by applicant]
Pharma Ingredients & Services Technical Information by BASF (Mar. 2012). [cited by applicant]
Polar Care—Product Insert (available via the Internet in Jun. 2017). [cited by applicant]
Remadevi and Szallasi, “Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for long-lasting pain relief,” IDrugs, vol. 11, pp. 120-132, (2008). [cited by applicant]
Shen et al. in Journal of Inclusion Phenomena and Macrocyclic Chemistry (2012) vol. 72, pp. 263-274. [cited by applicant]
Stevens et al. in “Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study,” in Annals of the Rheumatic Di… [cited by applicant]
Tateba et al. in Agric. Biol. Chem. (1991) vol. 55(3), pp. 873-874. [cited by applicant]
Turgut et al. in Environ. Sci. Pollut. Res. Int. (2004) vol. 11(1), pp. 7-10 (Abstract only). [cited by applicant]
Wong and Gavva, “Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks,” Brain Research Reviews 60, pp. 267-277, (2009). [cited by applicant]
Zhang et al. in Journal of Pain Research (2014) vol. 7, pp. 547-554. [cited by applicant]
Zhao et al. in Pharm Biol. (2016) vol. 54(1), pp. 130-138 (Abstract only). [cited by applicant]
BASF Pharma Ingredients & Services: Technical Information Soluplus (Jul. 2010). [cited by applicant]
Chang, A. et al., “Capsaicin,” [cited by applicant]
LaMotte, R.H. et al., “Neurogenic Hyperalgesia: Psychophysical Studies of Underlying Mechanisms,” [cited by applicant]
Green, “Sensory interactions between capsaicin and temperature in the oral cavity,” Chem Senses. 1986;11(3):371-82. [cited by applicant]
Warren et al., “Intra-articular Knee Temperature Changes: Ice Versus Cryotherapy Device,” Am J Sports Med. 2004;32(2):441-5. [cited by applicant]